We are live on ! Find out more
INBX

Inhibrx, Inc. Common Stock

Delisted

INBX was delisted on the 29th of May, 2024.

108 hedge funds and large institutions have $692M invested in Inhibrx, Inc. Common Stock in 2023 Q1 according to their latest regulatory filings, with 15 funds opening new positions, 37 increasing their positions, 34 reducing their positions, and 23 closing their positions.

New
Increased
Maintained
Reduced
Closed

4,404% more call options, than puts

Call options by funds: $4.19M | Put options by funds: $93K

9% more repeat investments, than reductions

Existing positions increased: 37 | Existing positions reduced: 34

0% more funds holding in top 10

Funds holding in top 10: 11 (0)

7% less funds holding

Funds holding: 116108 (-8)

22% less capital invested

Capital invested by funds: $886M → $692M (-$194M)

35% less first-time investments, than exits

New positions opened: 15 | Existing positions closed: 23

Holders
108
Holders Change
-8
Holders Change %
-6.9%
% of All Funds
1.72%
Holding in Top 10
1
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
0.02%
New
15
Increased
37
Reduced
34
Closed
23
Calls
$4.19M
Puts
$93K
Net Calls
+$4.1M
Net Calls Change
+$6.72M
Name Holding Trade Value Shares
Change
Change in
Stake
Renaissance Technologies
26
Renaissance Technologies
New York
$4.03M +$4.97M +213,500 New
Bank of America
27
Bank of America
North Carolina
$3.52M +$937K +40,274 +27%
Goldman Sachs
28
Goldman Sachs
New York
$3.31M +$68.9K +2,961 +2%
CS
29
Candriam SCA
Luxembourg
$3.25M
Rafferty Asset Management
30
Rafferty Asset Management
New York
$2.93M -$971K -41,769 -21%
Walleye Capital
31
Walleye Capital
New York
$2.88M -$1.26M -54,130 -26%
LNWWM
32
Laird Norton Wetherby Wealth Management
California
$2.57M +$2.21K +95 +0.1%
HighTower Advisors
33
HighTower Advisors
Illinois
$2.5M
Citigroup
34
Citigroup
New York
$2.35M +$880K +37,822 +44%
MWA
35
Meridian Wealth Advisors
Texas
$2.31M
PHS
36
PFM Health Sciences
California
$2.29M +$2.82M +121,447 New
Bank of New York Mellon
37
Bank of New York Mellon
New York
$1.99M -$49.7K -2,137 -2%
Wellington Management Group
38
Wellington Management Group
Massachusetts
$1.94M -$18.6M -798,085 -89%
Voloridge Investment Management
39
Voloridge Investment Management
Florida
$1.74M -$1.7M -72,965 -44%
D.E. Shaw & Co
40
D.E. Shaw & Co
New York
$1.71M -$242K -10,390 -10%
N
41
Nuveen
North Carolina
$1.67M +$930 +40 +0%
Jane Street
42
Jane Street
New York
$1.58M +$1.95M +83,885 New
Susquehanna International Group
43
Susquehanna International Group
Pennsylvania
$1.34M +$1.29M +55,262 +348%
BC
44
Birchview Capital
Vermont
$1.33M
CSS
45
Cubist Systematic Strategies
Connecticut
$1.21M +$444K +19,105 +43%
Barclays
46
Barclays
United Kingdom
$1.19M -$975K -41,942 -39%
TC
47
TwinBeech Capital
New York
$1.08M +$1.33M +57,095 New
Swiss National Bank
48
Swiss National Bank
Switzerland
$1.06M -$4.65K -200 -0.4%
Ensign Peak Advisors
49
Ensign Peak Advisors
Utah
$1.06M +$1.31M +56,173 New
UBS Group
50
UBS Group
Switzerland
$924K -$936K -40,265 -45%

INBX Hedge Fund Activity: Q1 2023 in Review

108 of the 6,276 institutional investors tracked by Wall St. Rank reported a position in Inhibrx, Inc. Common Stock (INBX) for Q1 2023, worth a combined $692M — down 22% from $886M a quarter earlier.

Sellers outnumbered buyers: 23 funds closed out of INBX and 15 opened new positions — a net loss of 8 holders — while 34 trimmed existing stakes and 37 added.

The largest buyer was Capital Research Global Investors, opening a new position worth an estimated $40.7M. The largest seller was Wellington Management Group, cutting an estimated $18.6M.

  • 108 institutional investors held Inhibrx, Inc. Common Stock (INBX) as of Q1 2023, down from 116 in Q4 2022.
  • Funds reported $692M of Inhibrx, Inc. Common Stock stock for Q1 2023, down 22% quarter-over-quarter.
  • 15 funds opened new Inhibrx, Inc. Common Stock positions in Q1 2023 and 23 closed out, a net change of -8 holders.
  • The largest Inhibrx, Inc. Common Stock buyer in Q1 2023 was Capital Research Global Investors, an estimated $40.7M added.
  • The largest Inhibrx, Inc. Common Stock seller in Q1 2023 was Wellington Management Group, an estimated $18.6M sold.

Based on aggregated 13F filings for Q1 2023.